Logo

BHS Guidelines

Consult the front-line and subsequent line treatment algorithms for CLL, MCL and WM developed by the Belgian Hematology Society Lymphoproliferative Working Party below.[1]
Based on new reimbursements and robust clinical data, the existing recommendations for CLL were updated in February 2020. Download the full overview of the recently published BHS Guidelines for SLL/CLL in pdf here[1]:

Diagnostic and/or pre-treatment work-up CLL [1]
Diagnostic and/or pre-treatment work-up CLL1
Front-Line CLL [1]
Front-Line CLL1

CLL: chronic lymphocytic leukemia; 17p del/p53 mut: 17p deletion/p53 mutation; unfit for FCR: Cr Cl <70 ml/min, CIRS >6, therapy-related cytopenia, history of autoimmune cytopenia; FCR: fludarabine, cyclophosphamide, rituximab; BR: bendamustine, rituximab; Ob: obinutuzumab; Chl: chlorambucil; R: rituximab ; allo-SCT: allogeneic stem cell transplantation

Relapsed/Refractory CLL [1]
Relapsed/Refractory CLL1

R/R: relapsed/refractory; CLL: chronic lymphocytic leukemia; 17p del/p53 mut: 17p deletion/p53 mutation; CIT: chemo-immunotherapy; R: rituximab; allo-SCT: allogeneic stem cell transplantation

Front-Line MCL[2]
Front-Line MCL2

MCL: mantle cell lymphoma; CIT: chemo-immunotherapy; IF RT: •involved field radiotherapy; Auto-SCT: autologous stem cell transplantation; R: rituximab; R-CHOP: rituximab-cyclophosphamide-adriamycine-vincristin-corticosteroids; R-DHAP:rituximab-cisplatinum-cytarabine-dexamethasone; BR: bendamustine-rituximab; VR-CAP: bortezomib-rituximab-cyclophosphamide-adriamycine-corticosteroids; HD CT: high dose chemotherapy

Relapsed/Refractory MCL[2]
Relapsed/Refractory MCL2

R/R MCL: relapsed/refractory mantle cell lymphoma; allo-SCT: allogeneic stem cell transplantation; CIT: chemo-immunotherapy; R: rituximab; R-DHAP:rituximab-cisplatinum-cytarabine-dexamethasone; BR: bendamustine-rituximab; HD ARA-C: high dose cytarabine

Front-Line WM[2]
Front-Line WM2

WM: Waldenström macroglobulinemia; CIT: chemo-immunotherapy; Auto-SCT: autologous stem cell transplantation; AIC: auto-immune cytopenia; PNP: polyneuropathy; R: rituximab; R-CP: rituximab- cyclophosphamide -prednisolone; R-CD: rituximab- cyclophosphamide-dexamethasone; BR: bendamustine- rituximab; BRD: bortezomib- rituximab-dexamethasone; R-Chl: rituximab-chlorambucil

Relapsed/Refractory WM[2]
Relapsed/Refractory WM2

R/R WM: relapsed/refractory Waldenström macroglobulinemia; CIT: chemo-immunotherapy; Auto-SCT: autologous stem cell transplantation; Allo-SCT: allogeneic stem cell transplantation

Reimbursement criteria Imbruvica
Find out here which patients can benefit from ibrutinib.[3]

Practical guide

Download the practical guide with reimbursement criteria and other practicalties on Imbruvica.

References

Janssens. BHS GUIDELINES FOR THE MANAGEMENT OF SMALL LYMPHOCYTIC LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA, ANNO 2020. Belgian Journal of Haematology 2020; 3: 108-119.
Janssens A., Vergote V., Van Hende V., Van Hoof A. et al. Updated Belgian Hematological Society guidelines for the treatment of chronic lymphocytic leukemia, mantle cell lymphomas and Waldenström’s macroglobulinaemia anno 2018. Belg J Haematol 2018;3:101-112